Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
T Cell-Depleted Peripheral Blood versus Unmanipulated Bone Marrow in Matched Sibling Transplantation for Aplastic Anemia.
Chorão P, Montoro J, Balaguer-Roselló A, Guerreiro M, Villalba M, Facal A, Solves P, Gómez-Segui I, Pasquini MC, Granados P, Bataller A, Louro A, de la Rubia J, Sanz MA, Sanz J. Chorão P, et al. Among authors: bataller a. Transplant Cell Ther. 2023 May;29(5):322.e1-322.e5. doi: 10.1016/j.jtct.2023.01.016. Epub 2023 Jan 20. Transplant Cell Ther. 2023. PMID: 36682469 Free article.
Reduced Incidence of Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation with Calcineurin-Free Graft-versus-Host Disease Prophylaxis.
Balaguer-Roselló A, Gil-Perotín S, Montoro J, Bataller L, Lamas B, Villalba M, Facal A, Guerreiro M, Chorão P, Bataller A, Granados P, Gómez I, Solves P, Louro A, de la Rubia J, Sanz MÁ, Sanz J. Balaguer-Roselló A, et al. Among authors: bataller a, bataller l. Transplant Cell Ther. 2023 Oct;29(10):610.e1-610.e12. doi: 10.1016/j.jtct.2023.07.008. Epub 2023 Jul 12. Transplant Cell Ther. 2023. PMID: 37451486
Cytomegalovirus Reactivations in Allogeneic Hematopoietic Stem Cell Transplantation from HLA-Matched and Haploidentical Donors with Post-Transplantation Cyclophosphamide.
Chorão P, Henriques M, Villalba M, Montoro J, Balaguer-Roselló A, González EM, Gómez MD, Gómez I, Solves P, Santiago M, Asensi P, Lamas B, Bataller A, Granados P, Eiris J, Martínez D, Louro A, Rebollar P, Perla A, Salavert M, de la Rubia J, Sanz MÁ, Sanz J. Chorão P, et al. Among authors: bataller a. Transplant Cell Ther. 2024 May;30(5):538.e1-538.e10. doi: 10.1016/j.jtct.2024.01.082. Epub 2024 Feb 6. Transplant Cell Ther. 2024. PMID: 38331195
Immune reconstitution after single-unit umbilical cord blood transplantation using anti-thymoglobulin and myeloablative conditioning in adults with hematological malignancies.
Cordón L, Chorão P, Martín-Herreros B, Montoro J, Balaguer A, Guerreiro M, Villalba M, Facal A, Asensi P, Solves P, Gómez I, Santiago M, Lamas B, Bataller A, Granados P, Sempere A, Sanz GF, Sanz MA, Sanz J. Cordón L, et al. Among authors: bataller a. Ann Hematol. 2024 Apr 18. doi: 10.1007/s00277-024-05758-0. Online ahead of print. Ann Hematol. 2024. PMID: 38634914
Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation.
Senapati J, Kantarjian HM, Bazinet A, Reville P, Short NJ, Daver N, Borthakur G, Bataller A, Jabbour E, DiNardo C, Haddad F, Sasaki K, Popat U, Oran B, Alousi AM, Loghavi S, Shpall E, Garcia-Manero G, Ravandi F, Kadia TM. Senapati J, et al. Among authors: bataller a. Cancer. 2024 May 29. doi: 10.1002/cncr.35388. Online ahead of print. Cancer. 2024. PMID: 38809547
Outcomes and genetic dynamics of acute myeloid leukemia at first relapse.
Bataller A, Kantarjian H, Bazinet A, Kadia T, Daver N, DiNardo CD, Borthakur G, Loghavi S, Patel K, Tang G, Sasaki K, Short NJ, Yilmaz M, Issa GC, Alvarado Y, Montalban-Bravo G, Maiti A, Abbas HA, Takahashi K, Pierce S, Jabbour E, Garcia-Manero G, Ravandi F. Bataller A, et al. Haematologica. 2024 May 2. doi: 10.3324/haematol.2024.285057. Online ahead of print. Haematologica. 2024. PMID: 38695144 Free article.
Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial.
Bazinet A, Kantarjian H, Bataller A, Pemmaraju N, Borthakur G, Chien K, Alvarado Y, Bose P, Jabbour E, Yilmaz M, DiNardo C, Issa G, Montalban-Bravo G, Short N, Sasaki K, Bull-Linderman D, Daver N, Garcia-Manero G, Ravandi F, Kadia T. Bazinet A, et al. Among authors: bataller a. Lancet Haematol. 2024 Apr;11(4):e287-e298. doi: 10.1016/S2352-3026(24)00034-6. Lancet Haematol. 2024. PMID: 38548404 Clinical Trial.
Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm.
Bataller A, Gener-Ricos G, Almanza-Huante E, Chien KS, Urrutia S, Bazinet A, Rodriguez-Sevilla JJ, Hammond D, Sasaki K, Takahashi K, DiNardo CD, Ravandi F, Borthakur G, Kadia TM, Kanagal-Shamanna R, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. Bataller A, et al. Blood Adv. 2024 Jun 11;8(11):2695-2706. doi: 10.1182/bloodadvances.2024012565. Blood Adv. 2024. PMID: 38513082
Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study.
Bazinet A, Garcia-Manero G, Short N, Alvarado Y, Bataller A, Abuasab T, Islam R, Montalbano K, Issa G, Maiti A, Yilmaz M, Jain N, Masarova L, Kornblau S, Jabbour E, Montalban-Bravo G, Rausch CR, Pierce S, DiNardo CD, Kadia T, Daver N, Konopleva M, Huang X, Kantarjian H, Ravandi F. Bazinet A, et al. Among authors: bataller a. Lancet Haematol. 2024 Apr;11(4):e276-e286. doi: 10.1016/S2352-3026(24)00033-4. Epub 2024 Mar 4. Lancet Haematol. 2024. PMID: 38452788 Clinical Trial.
73 results